Abbott India (ABBOTINDIA.NS) Osake Kurssi
Abbott India Kurssi
Viimeisten 19 vuoden aikana Abbott Indian liikevaihto kasvoi 14,7 % vuodessa ja ylsi 69,29 Mrd. INR:een. Osakekohtainen tulos on kasvanut 18,7 % vuodessa viimeisten 19 vuoden aikana. Abbott Indian nettomarginaali 22,4 % on noussut verrattuna 16,3 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,86 %. Jakosuhde on noin 61 % tuloksesta. Osinko on kasvanut 19,0 % vuodessa viimeisten 19 vuoden aikana. Abbott Indian 12 kuukauden konsensustavoitehinta on 37 740,00 INR, noin yli kurssia 47,9 %. 12 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Abbott India osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Abbott India liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Abbott India -osakkeesta
Abbott India Ltd operates as a leading pharmaceutical company in India. The company's business model primarily focuses on developing, manufacturing, and selling a wide range of healthcare products including pharmaceuticals, diagnostics, nutritional products, and medical devices. Abbott India Ltd follows a diversified approach by serving various therapeutic segments such as neuroscience, gastroenterology, women's health, cardiovascular, metabolic disorders, and more. The company strives to provide innovative and high-quality healthcare solutions to improve the lives of people in India. Abbott India Ltd continuously invests in research and development to bring new and advanced products to the market, reinforcing its position as a trusted and reliable pharmaceutical company.
Abbott India Ltd is primarily active in the pharmaceutical industry. As a leading player in the healthcare sector, Abbott India Ltd focuses on manufacturing and marketing a wide range of pharmaceutical products across multiple therapeutic categories. With its commitment to delivering high-quality healthcare solutions, Abbott India Ltd has established its presence in areas such as gastroenterology, women's health, neuroscience, and cardiovascular care. Through its innovative and diverse product portfolio, Abbott India Ltd strives to improve the lives of patients and contribute to the overall well-being of people in India.
The main competitors of Abbott India Ltd in the market include pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Dr. Reddy's Laboratories Ltd. These companies also operate within the Indian pharmaceutical market and offer a range of products and services similar to Abbott India Ltd. However, Abbott India Ltd distinguishes itself through its innovative product portfolio, strong brand reputation, and commitment to research and development.
Abbott India Ltd is a leading pharmaceutical company with a rich history and background. Established in India in 1944, Abbott India has been an integral part of the Indian healthcare sector for over 75 years. The company is a subsidiary of Abbott Laboratories, a global healthcare conglomerate based in the United States. Abbott India Ltd focuses on providing high-quality pharmaceutical products across various therapeutic areas, including neuroscience, gastroenterology, women's health, and cardiovascular diseases. With a strong commitment to innovation, research, and development, Abbott India Ltd has emerged as a trusted name in the Indian pharmaceutical industry, dedicated to improving people's lives through its wide range of healthcare solutions.
Abbott India Ltd has achieved several significant milestones throughout its existence. One noteworthy milestone was the company's establishment in India in 1910, showcasing its long-standing presence in the country. Another important achievement was the successful rebranding and divisional integration with Abbott Laboratories, a global healthcare leader. Additionally, Abbott India Ltd has consistently emerged as a reliable and innovative player in the pharmaceutical and healthcare industry, introducing various breakthrough products and technologies. The company's commitment to quality and patient care has earned it several accolades and certifications, further cementing its strong reputation in the market.
Abbott India Ltd is primarily present in India.
Abbott India Ltd represents a strong set of values and a customer-centric corporate philosophy. The company is committed to improving lives by providing high-quality healthcare products and services. Abbott India focuses on innovation, integrity, and excellence in all its operations, striving to make a positive impact on the healthcare industry. With a customer-driven approach, the company leverages advanced technologies and research to develop and deliver safe and effective healthcare solutions. Abbott India Ltd aims to be a trusted partner in meeting the diverse healthcare needs of the Indian population, reinforcing its commitment to improving overall well-being and driving sustainable growth.
Analyytikot asettavat tällä hetkellä Abbott India-osakkeelle keskimääräisen tavoitehinnan 37 760,40 INR (mediaani: 37 740,00 INR), mikä merkitsee +48,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 12 analyytikkoarvioon.
12 analyytikkoa arvioi tällä hetkellä Abbott India-osaketta: 11 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Abbott India-osake noteerataan hintaan 240,79 EUR (25 515,00 INR).
Abbott India Limited is a leading healthcare company focused on the development and marketing of medical devices, medical diagnostic tools, and pharmaceuticals. The company is headquartered in Mumbai and is a subsidiary of Abbott Laboratories, a global provider of healthcare products. Abbott India operates several business segments, including pharmaceuticals, medical devices, and diagnostics. It is involved in the pharmaceutical industry and offers a wide range of medications for various therapeutic areas such as gastrointestinal disorders, heart diseases, pain management, and antibiotics. The company works closely with its research and development teams to develop innovative medicines for patients worldwide. Abbott India Limited is also a leading provider of medical diagnostic tools, offering a wide range of diagnostic and screening solutions for various diseases such as HIV, hepatitis, diabetes, and cancer. Its products include blood glucose and cholesterol testing devices, rapid tests for infectious diseases, and various laboratory diagnostics. The company's diagnostics division is dedicated to improving healthcare through affordable and accessible testing solutions for a wider population. In addition to offering medications and diagnostic tools, Abbott India is also a leading provider of medical devices and equipment. The company offers a wide range of medical devices for various therapeutic areas, including artificial joints, cardiac implants, stents, and pacemakers. Additionally, the company also provides homecare products, including ventilators and insulin pumps, to enable convenient and cost-effective care for patients. Abbott India Limited strives to improve access to healthcare products and services through innovative business models. It works closely with healthcare providers, physicians, and government agencies to strengthen the healthcare system and improve treatment options. The company also offers various programs and initiatives to enhance patient care, including training and workshops for healthcare professionals to improve patient care. Overall, Abbott India is a leading provider of healthcare products and services focused on improving healthcare in India and globally. The company offers a wide range of medications, medical devices, and diagnostic tools, as well as training programs and initiatives to improve healthcare. Abbott India remains committed to developing innovative solutions and helping patients worldwide lead better lives.
liikevaihto Abbott India on 69,29 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Abbott India on 15,52 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Abbott India:n hinta-voitto-suhde (P/E) on tällä hetkellä 34,93. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Abbott India-osakkeen arvostusta.
Abbott India:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Abbott India-osakkeen arvostuskennuslukuna.
Abbott India:n Eulpool-laatuscore on 8/10.
Abbott India:n ISIN on INE358A01014. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Abbott India:n ticker on ABBOTINDIA.NS. Tämä pörssinoteeraus käytetään Abbott India-osakkeiden kauppaan pörssissä.
Abbott India osake
Abbott India vertaisryhmä
Abbott India FIGI
Kaikki tunnusluvut ja syvällinen analyysi Abbott India:sta
Meidän osakeanalyysimme Abbott India-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Abbott India:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: